Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extraction of Glaucoma Diagnosis, Type, and Severity from Clinical Notes using Secure Cloud-based Large Language Models.

medRxiv : the preprint server for health sciences·2026
Same author

GLLaucoMed: A Secure LLM-Powered Agentic Workflow for Automated Medication Extraction from Free-Text Glaucoma Clinical Notes.

medRxiv : the preprint server for health sciences·2026
Same author

Utilization of anterior segment optical coherence tomography in childhood glaucoma: A systematic review.

Survey of ophthalmology·2026
Same author

Beyond the Clinic: Home-Based Monitoring Strategies in Glaucoma Care.

International ophthalmology clinics·2026
Same author

Evaluating Large Language Models to Improve Spanish Patient Education on Childhood Glaucoma.

Journal of pediatric ophthalmology and strabismus·2026
Same author

Association between GLP-1 receptor agonist use and NAION with optic disc drusen.

Ophthalmology·2026

Related Experiment Video

Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Phosphodiesterase Type-5 Inhibitors and Glaucoma.

Abdelrahman M Elhusseiny1,2,3, Swarup S Swaminathan1

  • 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.

International Ophthalmology Clinics
|June 18, 2026
PubMed
Summary
This summary is machine-generated.

Phosphodiesterase type-5 (PDE5) inhibitors do not significantly affect intraocular pressure (IOP) but enhance choroidal blood flow. These PDE5 inhibitors may offer a protective association with glaucoma, requiring further investigation.

Keywords:
choroidal vasculatureglaucomaintraocular pressurephosphodiesterase type-5 inhibitors

More Related Videos

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Related Experiment Videos

Last Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Vascular Biology

Background:

  • Phosphodiesterase type-5 (PDE5) inhibitors are used for erectile dysfunction and impact nitric oxide signaling, relevant to ocular vascular health.
  • PDE5 is expressed in ocular tissues, prompting research into its effects on intraocular pressure (IOP), ocular blood flow, and glaucoma.
  • Existing research on PDE5 inhibitors and ocular health necessitates a comprehensive review of their safety and potential therapeutic implications.

Purpose of the Study:

  • To review clinical and experimental evidence on PDE5 inhibitors' effects on IOP, ocular perfusion, and glaucoma risk.
  • To clarify the ophthalmic safety profile of PDE5 inhibitors.
  • To explore potential therapeutic implications of PDE5 inhibitors in ocular conditions.

Main Methods:

  • Systematic review of clinical trials and experimental studies.
  • Analysis of data on intraocular pressure (IOP) changes.
  • Evaluation of studies on ocular blood flow, including choroidal and retinal perfusion.
  • Assessment of observational data and case reports related to glaucoma risk.

Main Results:

  • Most studies show no clinically significant or sustained effect of PDE5 inhibitors on intraocular pressure (IOP).
  • Evidence consistently indicates that PDE5 inhibition increases ocular blood flow, particularly in the choroid.
  • Observational analyses suggest PDE5 inhibitor use may be associated with a reduced risk of glaucoma diagnosis.

Conclusions:

  • PDE5 inhibitors have a neutral effect on IOP and enhance choroidal blood flow.
  • PDE5 inhibitors may have a protective association with glaucoma.
  • Further mechanistic and prospective studies are warranted to confirm these findings and explore therapeutic potential.